ProCE Banner Activity

SWOG S1406: Vemurafenib in Combination With Irinotecan and Cetuximab in BRAF V600E Metastatic CRC

Slideset Download
Conference Coverage
In this open-label phase II study, addition of vemurafenib associated with significantly improved PFS and clinical activity in BRAF V600E mCRC patients previously treated with systemic chemotherapy.

Released: June 12, 2017

Expiration: June 11, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology